Theis Muncholm Thillemann

Theis Muncholm Thillemann

Auto-generated profile, based on publicly available information

Theis Muncholm Thillemann

Department of Orthopaedic Surgery, Aarhus University Hospital, Aarhus N, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
PKP. K. Kristensen
P. K. Kristensen
TTT. M. Thillemann
T. M. Thillemann
APA. B. Pedersen
A. B. Pedersen
KSKjeld Soballe
Kjeld Soballe
SJS. P. Johnsen
S. P. Johnsen

7 February 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
STSara Kousgaard Tøstesen
Sara Kousgaard Tøstesen
Maiken StillingMaiken Stilling
Maiken Stilling
PHPelle Hanberg
Pelle Hanberg
TTTheis Muncholm Thillemann
Theis Muncholm Thillemann
TFThomas Falstie-Jensen
Thomas Falstie-Jensen
Mats BueMats Bue
Mats Bue
Deadspace is the tissue and bony defect in a surgical wound after closure. This space is presumably poorly perfused favouring bacterial proliferation and biofilm formation. In arthroplasty surgery, an obligate deadspace surrounding the prosthesis is introduced and deadspace management, in combination with obtaining therapeutic prophylactic antibiotic concentrations, is important for limiting the risk of acquiring a periprosthetic joint infection (PJI). This study aimed to investigate cefuroxime distribution to an orthopaedic surgical deadspace in comparison with plasma and bone concentrations during two dosing intervals (8 h × 2). In a setup imitating shoulder arthroplasty surgery, but without insertion of a prosthesis, microdialysis catheters were placed for cefuroxime sampling in a deadspace in the glenohumeral joint and in cancellous bone of the scapular neck in eighteen pigs. Blood samples were collected as a reference. Cefuroxime was administered according to weight (20 mg/kg). The primary endpoint was time above the cefuroxime minimal inhibitory concentration of the free fraction of cefuroxime for Staphylococcus aureus (fT > MIC (4 μg/mL)). During the two dosing intervals, mean fT > MIC (4 μg/mL) was significantly longer in deadspace (605 min) compared with plasma (284 min) and bone (334 min). For deadspace, the mean time to reach 4 μg/mL was prolonged from the first dosing interval (8 min) to the second dosing interval (21 min), while the peak drug concentration was lower and half-life was longer in the second dosing interval. In conclusion, weight-adjusted cefuroxime fT > MIC (4 μg/mL) and elimination from the deadspace was longer in comparison to plasma and bone. Our results suggest a deadspace consolidation and a longer diffusions distance, resulting in a low cefuroxime turn-over. Based on theoretical targets, cefuroxime appears to be an appropriate prophylactic drug for the prevention of PJI.

8 February 2022 in Acta Orthopaedica
Verified
Journal Article
Open access
PDF file
JLJosefine Beck Larsen
Josefine Beck Larsen
TTTheis Muncholm Thillemann
Theis Muncholm Thillemann
ALAntti P Launonen
Antti P Launonen
HØHelle Kvistgaard Østergaard
Helle Kvistgaard Østergaard
TFThomas Falstie-Jensen
Thomas Falstie-Jensen
EMElisabeth Mechlenburg Møller
Elisabeth Mechlenburg Møller
Background and purpose: Total shoulder arthroplasty (TSA) and shoulder exercises are both effective treatments for reducing pain and improving function in glenohumeral osteoarthritis. However, the effectiveness of TSA has not been compared with non-surgical treatment in a randomized controlled trial. We will examine whether TSA followed bystandard postsurgical rehabilitation is superior to a 12-week exercise program in patients with primary glenohumeral OA who are eligible for unilateral TSA. Patients and methods: In this Nordic multicenter randomized controlled clinical trial, patients with glenohumeral osteoarthritis eligible for TSA will be allocated to either TSA followed by usual care or exercise only. The exercise intervention comprises 12 weeks of exercise with one weekly physiotherapist-supervised session. Based on the sample size calculation, the trial needs to include 102 patients. Duration and outcome: Recruitment was initiated in April 2021 and is expected to be completed by the end of March 2024. Primary outcome is patient-reported quality of life, measured as total WOOS score 12 months after initiation of treatment. The key secondary outcomes include patient-reported pain intensity at rest and during activity; Disabilities of the Arm, Shoulder, and Hand score (DASH);the use of analgesics during the previous week; and adverse events. Trial registration: The trial is approved by the Central Denmark Region Committee on Biomedical Research Ethics (Journal No 1-10-72-29-21) and by the Danish Data Protection Agency (Journal No 1-16-02-199-21). ClinicalTrials.gov Identifier: NCT04845074.